Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ASKC202

Phase 1Small molecule

JJiangsu Aosaikang Pharmaceutical Co., Ltd.

ASKC202 is one of 13 small molecule programs targeting Tumor. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

12

Competitors

Pipeline

Status by Indication[3][1]

Indication

TumorRecruiting

TumorPhase 1

Recruiting

Competition

Competitive Landscape

13 competitors in Tumor

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Gemzar

Johnson & Johnson

Tuoyi

CCoherus Oncology, Inc.

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Giapreza

LLa Jolla Pharmaceutical Company

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

LM-302

LLaNova Medicines Zhejiang Co., Ltd.

MRI Contrast-Enhancing Agents

HP518 - Dose Expansion

HHinova Pharmaceuticals Aus Pty Ltd

ASK120067

JJiangsu Aosaikang Pharmaceutical Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Tumor

NCT05306132

Clinical

Trials by Indication[1]

Tumor1 trial

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067

Recruiting·JJiangsu Aosaikang Pharmaceutical Co., Ltd.·Phase 1·NCT05306132·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ASKC202. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ASKC202 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ASKC202. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Aosaikang Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJiangsu Aosaikang Pharmaceutical Co., Ltd.

Related News